期刊文献+

非小细胞肺癌低表达miR-100与不良预后相关的临床研究 被引量:2

Low expression of miR-100 and its poor prognosis related clinical research in non-small cell lung cancer
暂未订购
导出
摘要 目的研究microRNA-100(miR-100)在非小细胞肺癌中的表达水平及其与不良预后的相关性。方法从46例非小细胞肺癌组织及其相应癌旁组织中提取总RNA,使用qRT-PCR技术检测miR-100的表达量,分析miR-100表达水平与非小细胞肺癌预后之间的关系。结果 miR-100在40/46(86.9%)的肺癌肿瘤组织的表达要低于邻近正常组织;miR-100在Ⅱ期和Ⅲ、Ⅳ期患者的肿瘤组织中的相对表达水平要显著低于Ⅰ期患者;miR-100在化疗耐药的患者肿瘤组织中的相对表达水平也明显低于对化疗敏感的患者;miR-100低表达患者的DFS明显短于miR-100高表达患者。结论非小细胞肺癌癌组织中miR-100相对低表达与患者的不良预后相关,miR-100在未来有望作为预测肺癌预后的分子标志物之一。 Objective To assess the expression level of microRNA-100 (miR-100) and its poor prognosis related clinical research in non-small cell lung cancer(NSCLC). Methods Total RNA was extracted from 44 surgical specimens of NSCLC and corresponding adjacent tissues. MiR-100 expression was detected by qRT- PCR. The relationship between miR-100 expression level and prognosis was analyzed. Results MiR-100 expression was down-regulated in 86. 9% (40/46) of tumor tissue specimens. The relative expression level of miR- 100 in tumor tissues of patients with stage Ⅱ , Ⅲ and IV was significantly lower than that in patients with stage I. The relative expression level of miR-100 in patients with chemotherapy resistant patients was significantly lower than patients who respond to chemotherapy. Lower expression level of miR-100 was correlated with shorter dis- ease-free survival(DFS). Conclusions The relative low expression of miR-100 is associated with poor progno- sis, and may be used as one of the molecular markers to predict the prognosis of lung cancer in the future.
出处 《中国肿瘤外科杂志》 CAS 2016年第5期301-304,共4页 Chinese Journal of Surgical Oncology
基金 国家自然科学基金(81272532)
关键词 非小细胞肺癌 miR-100 肿瘤标志物 预后 Non-small cell lung cancer miRNA-100 Tumor marker Prognosis
  • 相关文献

参考文献14

  • 1BARTEL D P. MicroRNAs: genomics, biogenesis, mechanism,and function[J]_ Cell, 2004, 116(2) :281-297.
  • 2CUSHING L, JIANG Z, KUANG P, et al. The roles of mieroR- NAs and protein components of the microRNA pathway in lung de- velopment and diseases[J]_ Am J Respir Ceil Mol Bid, 2015, 52(4) :397-408.
  • 3ARIMA C, KAJINO T, TAMADA Y, et al. Lung adenocarcinoma subtypes definable by lung development-related miRNA expression profiles in association with clinicopathologic features[J]_ Carcino- genesis, 2014,35(10) :2224-2231.
  • 4WANG H, WU S, ZHAO L, et al. Clinical use of microRNAs as potential non-invasive biomarkers for detecting non-small cell lung cancer: a meta-analysis[ J]_ Respirology, 2015, 20( 1 ) :56-65.
  • 5DENG L, SHANG L, BAI S, et al. MicroRNA100 inhibits self- renewal of breast cancer stem-fike cells and breast tumor develop- ment[J]_ Cancer Res, 2014, 74(22) :6648-6660.
  • 6ZHOU M K, LIU X J, ZHAO Z G, et al. MicroRNA-100 functions as a tumor suppressor by inhibiting Lgr5 expression in colon cancer cells[J]_ Mol Meal Rep, 2015, 11(4) :2947-2952.
  • 7ZHANG N, FU H, SONG L, et al. MicroRNA-100 promotes mi- gration and invasion through mammalian target of rapamycin in e- sophageal squamous cell carcinoma [ J ]_ Oncol Rep, 2014, 32 (4) :1409-1418.
  • 8ALLEMANIC, WEIRH K, CARREIRAH, et al. Global surveil-lance of cancer survival 1995-2009 : analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries ( CONCORD-2 ) [ J ]_ Lancet, 2015, 385 (9972) : 977 -1010.
  • 9MONTANI F, BIANCHI F. Circulating cancer biomarkers : the mac- ro-revolufion of the micro-RNA[ J]_ EBioMedicine, 2016,5:4-6.
  • 10WOZNIAK M B, SCELO G, MULLER D C, et al. Circulating microRNAs as non-fnvasive biomarkers for early detection of non- small-Cell lung Cancer[J]. PLoS One, 2015, 10(5) :e0125026.

二级参考文献13

  • 1DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014 [ J ]. CA Cancer JClin, 2014,64 (4) : 252-271.
  • 2Farazi TA, Spitzer JI, Morozov P, et al. miRNAs in human cancer [J]. J Pathol, 2011,223(2) :102-115.
  • 3Jansson MD, Lund AH. MicroRNA and cancer[ J]. Mo! Oncol, 2012, 6(6) :590-610.
  • 4Cloonan N,Brown MK, Steptoe AL, et al. The miR-17-5p microR- NA is a key regulator of the G1/S phase cell cycle transition [ J ]. Genome Biol, 2008,9(8) :R127.
  • 5Ebi H, Sato T, Sugito N, et al. Counterbalance between RB inac- tivation and miR-17-92 overexpression in reactive oxygen species and DNA damage induction in lung cancers[J]. Oncogene, 2009, 28(38) :3371-3379.
  • 6Raponi M, Dossey L, Jatkoe T, et al. MicroRNA classifiers for predicting prognosis of squamous cell lung cancer [ J]. Cancer Res, 2009, 69(14):5776-5783.
  • 7Shan SW, Fang L, Shatseva T ,et al. Mature miR-17-Sp and pas- senger miR-17-3p induce hepatocellular carcinoma by targeting PTEN, GalNT7 and vimentin in different signal pathways [ J]. J Cell Sci, 2013,126(Pt 6) :1517-1530.
  • 8Yang X, Du WW, Li H, et al. Both mature miR-lT-Sp and passenger strand miR-17-3p target TIMP3 and induce prostate tumor growth and invasion[J]. Nucleic Acids Res,2013, 41(21):9688-9704.
  • 9Wang M, Gu H, Wang S, et al. Circulating miR-17-5p and miR-20a: molecular markers for gastric cancer[J]. Mol Med Report, 2012, 5(6) : 1514-1520.
  • 10Li H, Bian C, Liao L, et al. miR-17-5p promotes human breast cancer cell migration and invasion through suppression of HBP1 [ J]. Breast Cancer Res Treat, 2011,126 ( 3 ) : 565-575.

共引文献4

同被引文献4

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部